Biomarin Pharmaceutical INC (BMRN) — 10-Q Filings

10-Q Filings (6)

• BioMarin Swings to Q3 Loss on Soaring R&D, Revenue Up 3.7% — Oct 28, 2025 Risk: high
  BioMarin Pharmaceutical Inc. reported a net loss of $30.744 million for the three months ended September 30, 2025, a significant decline from a net income of $1
• BioMarin Q2 Revenue Jumps to $640M on Strong Product Sales — Aug 5, 2025 Risk: medium
  BioMarin Pharmaceutical Inc. reported total revenues of $640.0 million for the second quarter of 2025, a significant increase from $580.0 million in the second
• BioMarin Pharmaceutical Q1 2025 Update — May 2, 2025 Risk: medium
  BioMarin Pharmaceutical Inc. reported its first quarter 2025 results, ending March 31, 2025. The company's financial performance for the period is detailed in t
• BioMarin Pharma Q3 Revenue Rises to $590.6M — Oct 31, 2024 Risk: low
  BioMarin Pharmaceutical Inc. reported its third-quarter results for the period ending September 30, 2024. The company's revenue for the three months ended Septe
• BioMarin Pharmaceutical Q2 Revenue Edges Up to $620.5M — Aug 5, 2024 Risk: low
  BioMarin Pharmaceutical Inc. reported its second quarter 2024 results, ending June 30, 2024. The company's revenue for the three months ended June 30, 2024, was
• BioMarin Pharmaceutical Inc. Files 10-Q for Q1 2024 — Apr 26, 2024 Risk: low
  BIOMARIN PHARMACEUTICAL INC (BMRN) filed a Quarterly Report (10-Q) with the SEC on April 26, 2024. BioMarin Pharmaceutical Inc. reported its Q1 2024 results on

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX